Key result
Inferior vena cava resection and reconstruction yielded 78.4% 5-year primary venous patency and 48.7% overall survival, with R0 outperforming R1 resection.
Why the study?
Tumours involving the inferior vena cava are rare and require complex oncovascular surgery, for which standardised recommendations have only recently been proposed. This study evaluated perioperative, oncological, and vascular outcomes of inferior vena cava resection and reconstruction and assessed retrospective concordance with the 2025 Delphi Consensus.
What are the perioperative, oncological, and vascular outcomes of inferior vena cava resection and reconstruction in patients with malignant tumours involving the inferior vena cava?
Cohort (n=53)
No
What are the perioperative, oncological, and vascular outcomes of inferior vena cava resection and reconstruction in patients with malignant tumours involving the inferior vena cava?
Inferior vena cava oncovascular resection and reconstruction for malignancy can be performed with acceptable early mortality (7.5% at 90 days) and durable 5-year venous patency (78.4%) in experienced multidisciplinary centres, showing high concordance with the 2025 Delphi Consensus.
Answers are grounded in this paper and cite their sources.
Supports selected IVC resections in malignancy; extends 2025 Delphi Consensus but requires prospective confirmation.
Tumours involving the inferior vena cava are rare and require complex oncovascular surgery, for which standardised recommendations have only recently been proposed. This study evaluated perioperative, oncological, and vascular outcomes of inferior vena cava resection and reconstruction in a contemporary multidisciplinary cohort and assessed its retrospective concordance with the 2025 Delphi Consensus. We retrospectively reviewed 53 consecutive patients undergoing surgery for malignant tumours involving the inferior vena cava at a tertiary referral centre between February 2009 and April 2022. Clinical, operative, postoperative, oncological, and vascular outcomes were collected from a prospectively maintained database. Vena cava reconstruction was performed in 48 patients (91%), predominantly using ringed polytetrafluoroethylene interposition grafts. Complete (R0) tumour resection was achieved in 72% of patients. R0 resection was associated with significantly better 5-year overall survival (59.0% vs. 24.0%, p = 0.006) and recurrence-free survival (57.2% vs. 15.6%, p = 0.008) compared with R1 resection. In-hospital and 90-day mortality were 3.7% and 7.5%, respectively, while 21% required urgent reintervention during the index hospitalisation. At a median follow-up of 45 months, overall survival was 78.2% at 1 year and 48.7% at 5 years. Primary venous patency was 86.0% at 1 and 2 years and 78.4% at 5 years. Surgical management showed high retrospective concordance with the Delphi Consensus recommendations, published after the study period. Inferior vena cava oncovascular resection and reconstruction can be performed with acceptable early mortality and durable venous patency in experienced multidisciplinary centres. These findings support specialised referral and provide real-world data for further standardisation of reconstruction, anticoagulation, and surveillance strategies.
No takes yet. Share an insight, caveat, or question.
Caradu et al. (2026) conducted a cohort in Malignant tumours involving the inferior vena cava (n=53). Inferior vena cava oncovascular resection and reconstruction (complete R0 resection) vs. R1 resection was evaluated on 5-year overall survival (p=0.006). Inferior vena cava resection and reconstruction yielded 78.4% 5-year primary venous patency and 48.7% overall survival, with R0 outperforming R1 resection.
Synapse has enriched 10 related papers. Consider them for comparative context: